Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00349193 | A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod | PHASE2 | COMPLETED | 306 | — | — | Mar 1, 2005 | Aug 1, 2006 | Apr 8, 2011 | - | — |
| Arm | Type | Description |
|---|---|---|
| Laquinimod 0.3 mg | ACTIVE_COMPARATOR | Laquinimod 0.3 mg |
| Laquinimod 0.6 mg | ACTIVE_COMPARATOR | Laquinimod 0.6 mg |
| Placebo | PLACEBO_COMPARATOR | Blinded Placebo |
| Name | Type | Description |
|---|---|---|
| laquinimod 0.3 | DRUG | laquinimod 0.3mg |
| laquinimod 0.6 | DRUG | laquinimod 0.6mg |
| Placebo | OTHER | Blinded Placebo |
Inclusion Criteria: 1. Willing and able to give written informed consent 2. Confirmed MS diagnosis as defined by the McDonald criteria 3. R-R MS disease course. 4. At least one gadolinium-enhanced lesion on screening MRI 5. Women of child-bearing potential must practice a reliable method of birth c...